HKSecWiki新股资讯 2022年06月27日
10:41 PM EDT, 06/26/2022 (MT Newswires) -- Rainmed Medical (HKG:2297) on Monday launched its initial public offering in Hong Kong, whose listing pipeline is starting to get busy again as more companies emerge from the volatility-induced market lull.
美国东部时间2022年6月26日晚上10：41(MT Newwires)--Rainmed Medical(HKG：2297)周一在香港启动首次公开募股(IPO)，随着更多公司走出波动引发的市场平静，其上市流程开始再次繁忙。
The medical device maker will issue 23,348,000 shares at HK$4.28 to HK$6.24 each, a deal that could raise as much as HK$145.7 million ($18.6 million) if priced at the upper limit of the indicative range.
这家医疗器械制造商将以每股4.28港元至6.24港元的价格发行23,348,000股股票，如果定价在指导性区间的上限，这笔交易可能筹资至多1.457亿港元(合1,860万美元)。
Of the total shares on offer, 2.33 million are earmarked for Hong Kong investors. An overallotment option of up to 3.50 million shares can be exercised if there is strong demand for the IPO.
在此次发行的全部股票中，有233万股是为香港投资者指定的。如果IPO需求强劲，可以行使最多350万股的超额配售选择权。
The Suzhou-headquartered company, which counts Ping An Group (HKG:2318, SHA:601318) among its backers, expects to determine the listing price on June 30 and disclose the allocations on July 7.
这家总部位于苏州的公司的投资者包括平安集团(HKG：2318，SHA：601318)，预计将于6月30日确定发行价，并于7月7日披露分配情况。
Rainmed intends to start trading on the Hong Kong bourse on July 8.
Rainmed计划于7月8日在香港交易所开始交易。
Proceeds will be used to fund the ongoing research and development, further clinical studies and preparation for the registration filing, manufacturing and commercialization of its core products.
所得资金将用于正在进行的研究和开发、进一步的临床研究以及为其核心产品的注册申请、制造和商业化做准备。
Huatai Financial, Zhongtai International, BOCOM International, Eddid Securities and Livermore Holdings are the joint bookrunners and lead managers of the IPO.
华泰证券金融、中泰国际、交银国际、爱德华德证券和利华控股为此次IPO的联席账簿管理人和牵头经办人。
本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠，亦不会承担因任何不准确或遗漏而引起的任何损失或损害。
Was this helpful?
0 / 0
本文链接： https://www.hksecwiki.com/news/p16732355/
由HKSecWiki香港券商百科整理发布，香港证券开户请访问hksecwiki.com